The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2022

Filed:

May. 08, 2019
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Jesper Gromada, Concord, MA (US);

Viktoria Gusarova, Pleasantville, NY (US);

Amy Han, Hockessin, DE (US);

Sokol Haxhinasto, Brookfield, CT (US);

Christos Kyratsous, Irvington, NY (US);

Andrew J. Murphy, Croton-on Hudson, NY (US);

Thomas Nittoli, Pearl River, NY (US);

William Olson, Yorktown Heights, NY (US);

Matthew Sleeman, White Plains, NY (US);

Anna Zumsteg, Elmsford, NY (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 31/04 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 47/61 (2017.01); A61K 47/60 (2017.01); A61P 9/10 (2006.01); A61P 37/06 (2006.01); A61P 3/06 (2006.01); A61P 19/02 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/417 (2006.01); A61K 31/4985 (2006.01); A61K 31/5383 (2006.01); A61K 31/58 (2006.01); A61K 38/14 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/417 (2013.01); A61K 31/4985 (2013.01); A61K 31/5383 (2013.01); A61K 31/58 (2013.01); A61K 38/14 (2013.01); A61K 39/3955 (2013.01); A61K 47/60 (2017.08); A61K 47/61 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6889 (2017.08); A61P 3/06 (2018.01); A61P 9/10 (2018.01); A61P 19/02 (2018.01); A61P 31/04 (2018.01); A61P 37/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.


Find Patent Forward Citations

Loading…